Epratuzumab
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized (from mouse) |
| Target | CD22 |
| Clinical data | |
| Trade names | LymphoCide |
| ATC code | none |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
205923-57-5  |
| PubChem (SID) | 47206001 |
| IUPHAR/BPS | 8088 |
| DrugBank |
DB04958 |
| ChemSpider | none |
| UNII |
3062P60MH9  |
| KEGG |
D04036 |
| (what is this?) (verify) | |
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).[1][2]
Clinical trials
A clinical trial for relapsed adult acute lymphoblastic leukemia (ALL) has reported initial results.[3]
Results have been published for a phase II trial in untreated follicular lymphoma.[3]
Early results from a phase II trial for Diffuse large B-cell lymphoma (DLBCL) were encouraging.[3][4]
The manufacturers in August 2009 announced success in early trials against SLE,[5] and started two Phase III clinical trials.
July 2015 : Both phase III trials (EMBODY1/2) for SLE failed to meet their primary endpoint.[6]
Mechanism of action
Epratuzumab binds to the glycoprotein CD22 of mature and malignant B-cells.
Elevated CD22 and other B-cell receptor (BCR) proteins are associated with SLE. "Epratuzumab's mechanism of action transfers these BCR proteins to helper cells called effector cells which reduces B-cell destruction and epratuzumab's impact on the body's immune system"[6] via a process called trogocytosis.[3] (Other SLE therapies destroy B-cells which compromises the immune system.)
References
- ↑ Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties Clinical Cancer Research Vol. 9, September 1, 2003 free full text
- ↑ Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab Clinical Cancer Research Vol. 11, July 15, 2005 free full text
- 1 2 3 4 Epratuzumab
- ↑ Micallef et al. (2011). "Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma." (PDF). Blood. 118 (15): 4053–61. doi:10.1182/blood-2011-02-336990.
- ↑ Reuters: UCB and Immunomedics Announce Positive Results for Epratuzumab Phase IIb Study in Systemic Lupus Erythematosus (SLE)
- 1 2 Epratuzumab flunks two Phase 3 studies; Immunomedics plummets 42% premarket. July 28 2015